1. Home
  2. EVM vs ALLO Comparison

EVM vs ALLO Comparison

Compare EVM & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVM
  • ALLO
  • Stock Information
  • Founded
  • EVM 2002
  • ALLO 2017
  • Country
  • EVM United States
  • ALLO United States
  • Employees
  • EVM N/A
  • ALLO N/A
  • Industry
  • EVM Finance/Investors Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EVM Finance
  • ALLO Health Care
  • Exchange
  • EVM Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • EVM 213.2M
  • ALLO 236.2M
  • IPO Year
  • EVM N/A
  • ALLO 2018
  • Fundamental
  • Price
  • EVM $9.03
  • ALLO $1.09
  • Analyst Decision
  • EVM
  • ALLO Strong Buy
  • Analyst Count
  • EVM 0
  • ALLO 10
  • Target Price
  • EVM N/A
  • ALLO $8.88
  • AVG Volume (30 Days)
  • EVM 55.8K
  • ALLO 5.2M
  • Earning Date
  • EVM 01-01-0001
  • ALLO 08-15-2025
  • Dividend Yield
  • EVM 4.01%
  • ALLO N/A
  • EPS Growth
  • EVM N/A
  • ALLO N/A
  • EPS
  • EVM 0.20
  • ALLO N/A
  • Revenue
  • EVM N/A
  • ALLO N/A
  • Revenue This Year
  • EVM N/A
  • ALLO N/A
  • Revenue Next Year
  • EVM N/A
  • ALLO $199.63
  • P/E Ratio
  • EVM $47.61
  • ALLO N/A
  • Revenue Growth
  • EVM N/A
  • ALLO N/A
  • 52 Week Low
  • EVM $7.67
  • ALLO $0.86
  • 52 Week High
  • EVM $9.59
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • EVM 68.73
  • ALLO 38.08
  • Support Level
  • EVM $8.65
  • ALLO $1.07
  • Resistance Level
  • EVM $9.07
  • ALLO $1.50
  • Average True Range (ATR)
  • EVM 0.08
  • ALLO 0.13
  • MACD
  • EVM 0.05
  • ALLO -0.04
  • Stochastic Oscillator
  • EVM 100.00
  • ALLO 13.04

About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value

Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: